Cabaletta Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $223.72M
- P/E (TTM)
- –
- Dividend yield
- –
About Cabaletta Bio
Biological Products, (No Diagnostic Substances), SIC 2836
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies to provide deep, durable treatments for autoimmune conditions. Its proprietary CABA platform centers on Chimeric Antigen Receptor T cells for Autoimmunity, designed to eliminate disease-causing B cells and reset the immune system. The company's lead product candidate is rese-cel, a fully human CD19-targeting CAR T cell therapy. Its target patient populations include individuals suffering from autoimmune disorders such as dermatomyositis, anti-synthetase syndrome, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
The company's clinical development operations are based in the United States, where its target diseases affect patient populations ranging from 15,000 for pemphigus vulgaris to up to 320,000 for systemic lupus erythematosus, along with approximately 20,000 pemphigus vulgaris patients in Europe. Cabaletta Bio is developing rese-cel across multiple phase 1/2 cohorts and registrational cohorts through external manufacturing partnerships. The provided text does not state the company's headquarters location.
Summary of the business section of Cabaletta Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cabaletta Bio, Inc.
- Headquarters
- Philadelphia, PA
- Address
- 2929 Arch Street, Suite 600 19104
- Phone
- (267) 759-3100
- Website
- cabalettabio.com
- Employees
- 156, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- CABA
- Exchange
- Nasdaq
- IPO date
- Oct 25, 2019
- Shares outstanding
- 170M, Aug 7, 2026
- Public float
- $137.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1759138
- CUSIP
- 12674W109
- ISIN
- US12674W1099
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven Nichtberger | President & CEO, Director | 1,394,483 |
| David J. Chang | Chief Medical Officer | 8,800 |
| Arun Das | Chief Business Officer | – |
| Michael Gerard | General Counsel | 6,600 |
| Anup Marda | Chief Financial Officer | 50,000 |
| Gwendolyn Binder | President, Science & Tech. | 31,312 |
| Steve Gavel | Chief Commercial Officer | 22,170 |
| Catherine Bollard | Director | 5,405 |
| Scott C. Brun | Director | – |
| Mark Simon | Director | 154,205 |
| Shawn Tomasello | Director | 22,725 |
| Richard C. Henriques Jr | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steven Nichtberger | $1.94M | $1.65M | $973.27K | $24 | – |
| FY2024 Steven Nichtberger | $8.10M | -$8.63M | $3.35M | $25 | – |
| FY2023 Steven Nichtberger | $4.81M | $14.47M | $2.22M | $245 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 156 employees, 154 of whom were full-time and 2 whom were part-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 23, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |